Business
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif.,
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"Phase 1a Trial of Next-Generation Core Inhibitor, ABI-4334, Now Underway Following Clinical Trial Application (CTA) Clearance SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced financial results and recent highlights for the third quarter ended September 30, 2022. “During the third quarter, we have advanced clinical development of both of our next-generation, more potent core inhibitors with the Phase 1b study of 3733 on track to report initial data by the end of this year and the initiation of the first clinical study for 4334,” said John McHutchison, AO, MD, chief executive officer of Assembly Bio. “This quarter also marked the further expansion of our pipeline with the introduction of our first research programs outside of HBV and hepatitis delta virus. These programs, targeting high-recurrence genital herpes and transplant-associated herpesviruses, apply the deep expertise of our organization in small molecule antiviral drug development to develop differentiated approaches for viral diseases with significant unmet medical need. We are thrilled with the progress of our preclinical and clinical programs, and we remain encouraged about the potential for our next-generation core inhibitors with the recently presented data at AASLD and upcoming clinical data readout for 3733.” Recent Updates Received CTA clearance and initiated a blinded, placebo-controlled Phase 1a trial in New Zealand of the company’s next-generation investigational core inhibitor, ABI-4334 (4334), evaluating safety, tolerability and pharmacokinetics of single and multiple ascending doses of 4334 in healthy subjects.Introduced the first two new research programs expanding Assembly Bio’s portfolio beyond HBV and hepatitis delta virus (HDV): A long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor to treat high-recurrence genital herpes, andA pan-herpes non-nucleoside polymerase inhibitor to treat multiple transplant-associated herpesvirus infections. Announced the retirement of John McHutchison as chief executive officer (CEO) effective at the end of 2022 and the election of Jason Okazaki, currently president and chief operating off...